Table 2.
Antimicrobial Resistance Patterns of the Campylobacter coli and Campylobacter jejuni Isolates
| Isolate | Minimum Inhibitory Concentration, μg/mL | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMCa | CIPb,c | ERYb,c | FOS | GENd | MERa | TETb,c | RIF | AZMd,e | CLId | CHLd | |
| 42478 | 4 (S) | >32 (R) | >256 (R) | 16 (–) | >256 (R) | 0.064 (S) | >256 (R) | >32 (–) | >256 (R) | 32 (R) | 8 (S) |
| 43371 | 2 (S) | >32 (R) | >256 (R) | 16 (–) | >256 (R) | 0.32 (S) | >256 (R) | >32 (–) | >256 (R) | 32 (R) | 8 (S) |
| 48777 | 4 (S) | >32 (R) | 128 (R) | 64 (–) | 0.25 (S) | 0.125 (S) | >256 (R) | >32 (–) | 32 (R) | 256 (R) | 32 (R) |
| 76331 | 4 (S) | 16 (R) | >256 (R) | 32 (–) | 0.5 (S) | 0.032 (S) | >256 (R) | >32 (–) | >256 (R) | 8 (R) | 16 (S) |
| 138449 | 4 (S) | >32 (R) | >256 (R) | 32 (–) | 0.25 (S) | 0.5 (S) | >256 (R) | >32 (–) | >256 (R) | 8 (R) | 8 (S) |
| 143854 | 4 (S) | >32 (R) | >256 (R) | 32 (–) | 0.125 (S) | 0.5 (S) | >256 (R) | >32 (–) | >256 (R) | 8 (R) | 8 (S) |
| 143970 | 8 (R) | >32 (R) | >256 (R) | 64 (–) | 0.125 (S) | 0.5 (S) | >256 (R) | >32 (–) | >256 (R) | 16 (R) | 8 (S) |
| 148558 | 4 (S) | >32 (R) | >256 (R) | 32 (–) | 0.125 (S) | 0.125 (S) | >256 (R) | >32 (–) | >256 (R) | 8 (R) | 8 (S) |
| 158403 | 8 (R) | >32 (R) | >256 (R) | 16 (–) | 0.5 (S) | 0.5 (S) | >256 (R) | >32 (–) | >256 (R) | 16 (R) | 16 (S) |
| S871 | 16 (R) | >32 (R) | >256 (R) | 64 (–) | 0.25 (S) | 1.0 (S) | >256 (R) | >32 (–) | … | … | … |
| SP15-082 | 8 (S) | >32 (R) | >256 (R) | >1024 (–) | 0.25 (S) | 0.5 (S) | >256 (R) | >32 (–) | >256 (R) | 16 (R) | 32 (R) |
| SP16-070 | 8 (S) | >32 (R) | >256 (R) | 32 (–) | 0.5 (S) | 0.5 (S) | >256 (R) | >32 (–) | >256 (R) | 32 (R) | 16 (S) |
| SP18-054 | 4 (S) | >32 (R) | >256 (R) | 16 (–) | >256 (R) | 0.064 (S) | >256 (R) | >32 (–) | >256 (R) | 64 (R) | 8 (S) |
| SP18-090 | 2 (S) | >32 (R) | >256 (R) | 16 (–) | >256 (R) | 0.032 (S) | >256 (R) | >32 (–) | >256 (R) | 64 (R) | 16 (S) |
| SP18-232 | 4 (S) | >32 (R) | 128 (R) | 64 (–) | 0.125 (S) | 0.5 (S) | >256 (R) | >32 (–) | >256 (R) | 4 (R) | 4 (S) |
| 18–164 | 4 (S) | >32 (R) | >256 (R) | 32 (–) | 0.25 (S) | 0.008 (S) | 0.5 (S) | >32 (–) | >256 (R) | 128 (R) | 4 (S) |
| HMC314 | 4 (S) | 8 (R) | >256 (R) | 32 (–) | 0.25 (S) | 0.016 (S) | 0.25 (S) | >32 (–) | >256 (R) | 16 (R) | 4 (S) |
| SP17-196 | 4 (S) | >32 (R) | >256 (R) | 32 (–) | 0.25 (S) | 0.5 (S) | >256 (R) | >32 (–) | 32 (R) | 256 (R) | 256 (R) |
Susceptibility interpretations are from the Clinical and Laboratory Standards Institute (CLSI) and/or the European Committee on Antimicrobial Susceptibility Testing (EUCAST). (–) Indicates no CLSI or EUCAST interpretation.
Abbreviations: AMC, amoxicillin–clavulanic acid; AZM, azithromycin; CHL, chloramphenicol; CIP, ciprofloxacin; CLI, clindamycin; ERY, erythromycin; FOS, fosfomycin; GEN, gentamicin; MER, meropenem; R, resistant; RIF, rifampin; S, susceptible; TET, tetracycline.
aEUCAST pharmacokinetic/pharmacodynamic (non–species related) breakpoints version 9.0.
bCLSI M45 3rd edition: 2016 breakpoints.
cEUCAST breakpoints version 9.0.
dEUCAST epidemiologic cutoff value (accessed 6 August 2019).
eEUCAST breakpoints version 9.0; note that ERY susceptibility can be used to determine AZM susceptibility.